Cardiac troponin and COVID-19 severity: Results from BIOCOVID study.
Luis García de Guadiana RomualdoDaniel Morell-GarcíaOlaia Rodríguez-FragaCristian Morales-IndianoAna María Lourdes Padilla JiménezJosé Ignacio Gutiérrez RevillaEloísa UrrechagaJosé María ÁlamoAna María Hernando HolgadoMaría Del Carmen Lorenzo-LozanoSilvia Sánchez Fdez-PachecoPatricia de la Hera CagigalMaría Ángeles Juncos TobarraJuan A VílchezIsabel Vírseda ChamorroIrene Gutiérrez GarciaYolanda Pastor MurciaLaura Sahuquillo FríasLaura Altimira QueralElisa Nuez-ZaragozaJuan Adell Ruiz de LeónAlicia Ruiz RipaPaloma Salas Gómez-PablosIria Cebreiros LópezAmaia Fernández UriarteÁlex LarruzeaMaría Luisa López YepesNatalia Sancho-RodríguezMaría Consuelo Zamorano AndrésJosé Pedregosa DíazCristina Acevedo AlcarazAlfonso-L Blázquez ManzaneraSonia Pérez SanmartínMaría Del Carmen Baamonde CalzadaMarina VeraElena Valera NuñezMagdalena Canalda CampásSara García MuñozJosep Miquel BauçaLuis Vicente GutiérrezLaura Jiménez AñónAlfonso Pérez MartínezAurelio Pons CastilloRuth González TamayoJorge Férriz VivancosMaría José Alcaide MartínVicente Ferrer Díaz de Brito FernándezVicente AguaderoMaría Gloria García ArévaloMaría Arnaldos CarrilloMercedes González MoralesMaría Núñez GárateCristina Ruiz IruelaPatricia Esteban TorrellaMartí Vila PérezJose Manuel Egea-CaparrósLuis SáenzAmparo Galán OrtegaLuciano Consuegra-SánchezPublished in: European journal of clinical investigation (2021)
In this multicentre study, myocardial injury was a common finding in COVID-19 patients. Its prevalence increased when a sex-specific cut-off and cardiac troponin T were used. Elevated troponin was an independent predictor of 30-day mortality, irrespective of cardiac troponin assay and cut-offs to detect myocardial injury. Hence, the early measurement of cardiac troponin may be useful for risk stratification in COVID-19.